Here is a new article published this month. This is mainly relating to men and men's risks, but some relevant info.to us, too.
Looks like there is no effective Oral HPV test at present, whilst smear test is only to detect the cervical pre-cancer cells.
There is no discussion re. the safety of passing HPV via reversal oral either. As we are a high-risk group (given the "unusually" high number of oral sex partners, I would be interested in this type of oral HPV test. "If it happens down below...why it wouldn't elsewhere...?" We have known that curable STIs may/might happen in one's throat. It's not a zero-risk whilst we wish that was the case. Russian roulette comes to my mind. What I dislike about this is that how do I explain it to a consultant if I ended up with this trouble and if he asks me how many oral sex partners have I had in a year?
Understanding personal risk of oropharyngeal cancer: risk-groups for oncogenic oral HPV infection and oropharyngeal cancer
G D?Souza T S McNeel C Fakhry
Annals of Oncology (Oxford Academic)
Published: 19 October 2017
"Human papillomavirus (HPV) is the most commonly sexually transmitted infection in the United States. HPV now causes ∼70% of all oropharyngeal squamous cell cancer (OPC) in the United States [1] and the incidence of HPV-related OPC (HPV-OPC) among men has more than doubled over the past 20 years [2]. Indeed, OPC is projected to be more common than cervical cancer in the United States by 2020 [3]. Given the ?epidemic? of HPV-OPC, there is interest in identifying specific groups that could benefit from screening, if effective tests were developed.
Sexual behaviors responsible for exposure to oral HPV infection are common (80% of the US population reports ever performing oral sex) [4]. Given the ubiquitous exposure to HPV infection and resulting anxiety [5], there is interest in identifying healthy individuals most at risk for development of OPC. As oncogenic oral HPV infection is the precursor to malignancy, identification of individuals with oncogenic oral HPV infection may point to individuals with premalignant disease. Such risk triage could both inform screening approaches and assist the public in understanding personal risk. This analysis therefore aims to understand how common HPV16, oncogenic HPV and HPV-OPC are in groups of people with different risk factor profiles."
academic.oup.com/annonc/article/doi/10.1093/annonc/mdx535/4554825/Understanding-personal-risk-of-oropharyngeal